MetLife, Inc. filings document the regulatory record of a Delaware financial services company with NYSE-listed common stock and preferred securities, including depositary shares tied to Series E and Series F preferred stock. Recent Form 8-K reports furnish earnings releases, quarterly financial supplements, total assets under management fact sheets and Regulation FD disclosures related to variable investment income.
The filings also cover capital-structure actions such as subordinated debenture issuance and preferred stock dividend declarations. Proxy materials describe board composition, committee assignments, executive compensation and shareholder voting matters, while material-event reports record governance changes and other corporate disclosures.
MetLife director Daniel S. Glaser reported a small share award. On June 9, 2026, he acquired 7 shares of MetLife common stock at $85.57 per share through a grant tied to the MetLife Deferred Compensation Plan for Non-Management Directors. After this award, he holds 2,108 shares directly and 198 shares indirectly in a GRAT.
MetLife Inc. director Robert Glenn Hubbard acquired 678 shares of Common Stock as a compensation-related award. The shares were credited on June 9, 2026 at $85.57 per share as an imputed reinvestment of dividends on deferred shares under the MetLife Deferred Compensation Plan for Non-Management Directors.
After this transaction, Hubbard directly holds 106,557 MetLife common shares. The filing characterizes the event as a grant or award, not an open-market purchase.
MetLife Inc. reported that President, U.S. Business Ramy Tadros acquired 127 shares of common stock on June 9, 2026. The shares were credited at an imputed price of $85.57 per share through reinvested dividends in the MetLife Leadership Deferred Compensation Plan, increasing his direct holdings to 216,946 shares. This reflects routine compensation-related accrual rather than an open-market purchase.
MetLife EVP & Chief Risk Officer Marlene Debel reported option exercises and share sales in common stock. On June 1, 2026, she exercised employee stock options to acquire 10,712 shares at $45.50 and 10,600 shares at $46.85 per share. The same day, she completed an open‑market sale of 21,312 shares at a weighted average price of $81.5889, with individual trade prices between $81.57 and $81.65. Following these transactions, she directly owns 154,380 shares of MetLife common stock.
MET submitted a Rule 144 notice reporting proposed sales of Common stock on 06/01/2026. The excerpt lists securities to be sold tied to options granted 02/28/2017 (10,600 shares) and 03/02/2018 (10,712 shares), each shown with a cash settlement method.
MetLife, Inc. filed a Form 144 reporting intended sales of Common Stock, listing multiple small blocks sold in March–April 2026. The filing shows an entry of 725 shares on 03/02/2026 and several other lots (for example, 145 shares on 03/20/2026 and 121 shares on 04/02/2026).
MetLife, Inc. declared second quarter 2026 dividends on three series of preferred stock. The quarterly dividend is $0.31190376 per share on its floating rate non-cumulative preferred stock, Series A, which has a $25 per share liquidation preference.
Holders of the 5.625% non-cumulative preferred stock, Series E, will receive $351.5625 per share, equal to $0.3515625 per depositary share, based on a $25,000 per share liquidation preference. The 4.75% non-cumulative preferred stock, Series F, will pay $296.875 per share, or $0.296875 per depositary share, also on a $25,000 liquidation preference.
All these preferred dividends are payable on June 15, 2026, to shareholders of record as of May 29, 2026.
MetLife Inc. filed a Form 13F-HR reporting holdings on behalf of its investment management subsidiaries. The filing states a Form 13F Information Table Entry Total of 6 and a Form 13F Information Table Value Total of $12,335,766. The report is signed by John McCallion on 05-14-2026.
MetLife, Inc.’s board of directors, as an entity, reports beneficial ownership of 103,885,196 shares of common stock, representing 16.2% of the company’s outstanding shares as of April 30, 2026. These shares are held in the MetLife Policyholder Trust created under MetLife’s demutualization plan.
The board is deemed to beneficially own the trust shares because it directs how they are voted on most stockholder matters, while policyholder beneficiaries retain economic rights such as dividends and sale proceeds. Trust holdings have steadily declined from 494,466,664 shares issued to the trust in 2000, including a recent decrease from 105,374,380 shares to 103,885,196 shares due to beneficiary-related transactions.
MetLife reported solid Q1 2026 results with higher earnings and stable balance sheet strength. Total revenues were $19,074 million, up from $18,569 million a year earlier, driven by premiums of $12,120 million and net investment income of $5,355 million.
Net income attributable to MetLife, Inc. was $1,185 million versus $945 million, with net income available to common shareholders of $1,140 million compared to $879 million. Basic earnings per common share rose to $1.75 from $1.29, and diluted EPS increased to $1.74 from $1.28.
Total consolidated adjusted earnings across segments reached $1,631 million, up from $1,415 million, with particularly strong contributions from Asia, Group Benefits and RIS. Operating cash flow was $2,687 million, while MetLife returned capital through $372 million of common dividends and treasury stock repurchases of $762 million. The company ended the quarter with total assets of $743,211 million and total equity of $27,595 million, and continued integrating its Strategic Reorganization and the PineBridge Investments acquisition within the MIM segment.